News

SEATTLE, Wash and VANCOUVER, British Columbia, June 3, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 16/993,522 (the ‘522 Application)…

SEATTLE, Wash. and VANCOUVER, British Columbia, March 15, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to the company’s Board of Directors,…

SEATTLE, Wash. and VANCOUVER, British Columbia, March 14, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Vaughn Himes to the company’s Board of Directors, effective immediately. “We are…

SEATTLE, Wash. and VANCOUVER, British Columbia, February 3, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations….

SEATTLE, Wash. and VANCOUVER, British Columbia, September 30, 2020 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the promotion of John Bencich to Chief Executive Officer. Mr. Bencich has been serving as Achieve’s Chief Financial and Operating…